Another study will evaluate the efficacy and safety of giredestrant compared with fulvestrant, both in combination with the physician’s choice of a CDK4/6 inhibitor (ClinicalTrials.gov identifier: NCT06065748) in patients with ER+, HER2− advanced breast cancer who have developed resistance to adjuvant endocrine therapy. The gene discussed is ERBB2; the disease is breast carcinoma.